Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone858-794-8889
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$151.86 million
Profitability
Miscellaneous
Employees281
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How were Halozyme Therapeutics' earnings last quarter?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.07. The biopharmaceutical company had revenue of $39.10 million for the quarter, compared to analyst estimates of $42.94 million. Halozyme Therapeutics had a negative net margin of 23.53% and a negative return on equity of 16.97%. Halozyme Therapeutics's revenue was up 11.1% compared to the same quarter last year. During the same period last year, the company posted ($0.16) earnings per share. View Halozyme Therapeutics' Earnings History.
When is Halozyme Therapeutics' next earnings date?
What guidance has Halozyme Therapeutics issued on next quarter's earnings?
Halozyme Therapeutics updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $205-215 million, compared to the consensus revenue estimate of $204.91 million.
What price target have analysts set for HALO?
3 analysts have issued 1 year price targets for Halozyme Therapeutics' shares. Their forecasts range from $17.00 to $27.00. On average, they anticipate Halozyme Therapeutics' share price to reach $21.67 in the next twelve months. This suggests a possible upside of 41.2% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics.
What is the consensus analysts' recommendation for Halozyme Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Halozyme Therapeutics.
What are Wall Street analysts saying about Halozyme Therapeutics stock?
Here are some recent quotes from research analysts about Halozyme Therapeutics stock:
- 1. According to Zacks Investment Research, "Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine. " (8/7/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $24 PT per share on HALO. Halozyme reported 1Q19 revenues of $57M, which were below our and FactSet consensus estimates of $62M and $69M, respectively. Additionally, the company ended 1Q19 with cash of ~$329M, and we model current cash and projected ENHANZE royalties to fund HALO through key value-creating milestones. During 1Q19, royalty revenues declined by 14% YoY, mainly due to lower sales of Herceptin SC in Europe, which were partially offset by higher sales of RITUXAN HYCELA versus 1Q18." (5/8/2019)
Has Halozyme Therapeutics been receiving favorable news coverage?
News articles about HALO stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Halozyme Therapeutics earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Halozyme Therapeutics.
Who are some of Halozyme Therapeutics' key competitors?
Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of Halozyme Therapeutics own?
Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the folowing people:
- Dr. Helen I. Torley, Pres, CEO & Director (Age 56)
- Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)
- Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)
- Dr. Dimitrios Chondros, Chief Medical Officer & Sr. VP (Age 54)
- Mr. Benjamin J. Hickey, Sr. VP & Chief Commercial Officer (Age 44)
Who are Halozyme Therapeutics' major shareholders?
Halozyme Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Taylor Wealth Management Partners (0.14%), Nisa Investment Advisors LLC (0.01%) and Coastal Investment Advisors Inc. (0.01%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros and Randal J Kirk. View Institutional Ownership Trends for Halozyme Therapeutics.
Which major investors are selling Halozyme Therapeutics stock?
Which major investors are buying Halozyme Therapeutics stock?
How do I buy shares of Halozyme Therapeutics?
Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Halozyme Therapeutics' stock price today?
One share of HALO stock can currently be purchased for approximately $15.34.
How big of a company is Halozyme Therapeutics?
Halozyme Therapeutics has a market capitalization of $2.24 billion and generates $151.86 million in revenue each year. The biopharmaceutical company earns $-80,330,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.View Additional Information About Halozyme Therapeutics.
What is Halozyme Therapeutics' official website?
How can I contact Halozyme Therapeutics?
Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]
MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.
